Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV002952513 | SCV003268075 | uncertain significance | not provided | 2022-07-29 | criteria provided, single submitter | clinical testing | This sequence change replaces serine, which is neutral and polar, with leucine, which is neutral and non-polar, at codon 1804 of the LAMA5 protein (p.Ser1804Leu). This variant is present in population databases (rs149570905, gnomAD 0.1%), including at least one homozygous and/or hemizygous individual. This variant has not been reported in the literature in individuals affected with LAMA5-related conditions. Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Tolerated"; PolyPhen-2: "Possibly Damaging"; Align-GVGD: "Class C0"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Prevention |
RCV003395541 | SCV004118897 | uncertain significance | LAMA5-related disorder | 2023-05-02 | criteria provided, single submitter | clinical testing | The LAMA5 c.5411C>T variant is predicted to result in the amino acid substitution p.Ser1804Leu. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.11% of alleles in individuals of European (Finnish) descent in gnomAD, including one homozygote (http://gnomad.broadinstitute.org/variant/20-60900490-G-A). Although we suspect that this variant may be benign, at this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |
Ambry Genetics | RCV005356223 | SCV006018386 | uncertain significance | Inborn genetic diseases | 2025-01-29 | criteria provided, single submitter | clinical testing | The c.5411C>T (p.S1804L) alteration is located in exon 41 (coding exon 41) of the LAMA5 gene. This alteration results from a C to T substitution at nucleotide position 5411, causing the serine (S) at amino acid position 1804 to be replaced by a leucine (L). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |